Affimed N.V. (AFMD)
NASDAQ: AFMD · IEX Real-Time Price · USD
5.21
+0.05 (1.07%)
At close: Jul 23, 2024, 4:00 PM
5.31
+0.10 (1.92%)
After-hours: Jul 23, 2024, 5:16 PM EDT

Company Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany.

The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.

It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.

It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.

The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014.

Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Affimed N.V.
Affimed logo
Country Germany
Founded 2000
IPO Date Sep 12, 2014
Industry Biotechnology
Sector Healthcare
Employees 76
CEO Dr. Andreas Harstrick M.D.

Contact Details

Address:
Gottlieb-daimler-strasse 2
Mannheim, 2M 68165
Germany
Phone 49-621-560030
Website affimed.com

Stock Details

Ticker Symbol AFMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
CIK Code 0001608390
CUSIP Number N01045108
ISIN Number NL0015001ZQ0
SIC Code 2834

Key Executives

Name Position
Dr. Andreas Harstrick M.D. Interim Chief Executive Officer, Chief Medical Officer and Member of Management Board
Dr. Wolfgang Fischer Ph.D. MD, Chief Operating Officer and Member of Management Board
Denise Mueller Chief Business Officer and Member of Management Board
Prof. Melvyn Little Founder and Consultant
Michael Wolf Head of Finance and Administration
Alexander Fudukidis Head of Investor Relations and Director of Investor Relations
Mary Beth Sandin Vice President of Marketing and Communications

Latest SEC Filings

Date Type Title
Jun 26, 2024 6-K Report of foreign issuer
Jun 12, 2024 6-K Report of foreign issuer
Jun 6, 2024 6-K/A Filing
Jun 3, 2024 6-K Report of foreign issuer
May 28, 2024 6-K Report of foreign issuer
May 23, 2024 6-K Report of foreign issuer
Mar 28, 2024 6-K Report of foreign issuer
Mar 28, 2024 20-F Annual and transition report of foreign private issuers
Mar 11, 2024 6-K Report of foreign issuer
Mar 6, 2024 6-K Report of foreign issuer